Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

• Reck, Martin LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany;
• Karagiannis, Tom Genentech, Inc., South San Francisco, CA;
• Wehler, Thomas Universitätsklinikum des Saarlandes, Homburg, Germany;
• Shtivelband, Mikhail Ironwood Cancer and Research Centers, Chandler, AZ;
• Gonzalez-Larriba, Jose-Luis Hospital Clinico San Carlos, Madrid, Spain;
• Rothenstein, Jeffrey Durham Regional Cancer Center, Lakeridge Health, Oshawa, ON, Canada;
• Frueh, Martin Kantonsspital St Gallen, St Gallen, Switzerland;
• Deng, Yu Genentech, Inc., South San Francisco, CA;
• Lopez-Chavez, Ariel Genentech, Inc., South San Francisco, CA;
• Sandler, Alan Genentech, Inc., South San Francisco, CA;
• Socinski, Mark A. Florida Hospital Cancer Institute, Orlando, FL;

Cancer Research

Oncology